You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: December 2019 to June 2025

AbstractFullPdf
Dec 2019110
Jan 2020990
Feb 202022221
Mar 202032324
Apr 202021219
May 202040407
Jun 202026263
Jul 202033335
Aug 202025232
Sep 202033331
Oct 202047479
Nov 202032325
Dec 202048486
Jan 2021292712
Feb 202146463
Mar 2021222214
Apr 202133335
May 2021404012
Jun 202128286
Jul 202122228
Aug 202112126
Sep 2021363626
Oct 2021242423
Nov 2021373729
Dec 2021202211
Jan 202228309
Feb 2022273021
Mar 2022454625
Apr 2022343512
May 2022343413
Jun 2022393921
Jul 2022424319
Aug 2022434410
Sep 2022323318
Oct 2022666927
Nov 2022293120
Dec 2022424214
Jan 2023505717
Feb 2023575711
Mar 2023464711
Apr 2023242611
May 2023323219
Jun 202320206
Jul 202323237
Aug 202314144
Sep 202322247
Oct 2023393913
Nov 2023353715
Dec 2023202010
Jan 202428296
Feb 2024464620
Mar 2024353613
Apr 2024656519
May 2024585812
Jun 2024272912
Jul 2024616817
Aug 2024333314
Sep 2024454518
Oct 2024575739
Nov 20245456122
Dec 2024404244
Jan 2025424220
Feb 2025505015
Mar 2025515128
Apr 2025828216
May 2025505114
Jun 202526267
Total24112454983